AM Best has affirmed the credit ratings of Blue Whale Re Ltd., Pfizer Inc.'s sole captive insurer. The agency maintained the financial strength rating at A (Excellent) and the long-term issuer credit rating at "a+" (Excellent), with a stable outlook on both.
AM Best assessed Blue Whale's balance sheet strength as very strong. The agency cited strong operating performance, a neutral business profile, and an appropriate enterprise risk management (ERM) programme as underpinning the affirmation.
Blue Whale Re is domiciled in Burlington, Vermont, the largest captive domicile globally. Vermont held 683 licensed captives at year-end 2024, according to the Vermont Department of Financial Regulation.
The broader captive market continues to grow. An AM Best report found that the number of US domestic captives rose to 3,466 in 2024 from 3,365 the prior year. Captives now generate roughly one-quarter of global re/insurance market premium, driven by sustained hard market conditions.
Blue Whale covers Pfizer's international employee benefits and global property exposures, among other lines. AM Best said the captive plays a role in Pfizer's ERM framework by protecting assets across the company's global operations.
Blue Whale provides retentions in coverages for Pfizer, supplemented by reinsurance capacity. In hard market conditions, it has taken small participations in its own catastrophe tower as a cost-efficiency measure for the Pfizer enterprise.
The captive has also provided capacity for cyber liability coverage in response to hard market pricing. AM Best noted that losses from low-frequency, high-severity exposures have not compromised the captive's operating performance.
AM Best said its stable outlook is based on an expectation that Blue Whale will continue to produce operating results that support its capitalisation. The agency does not expect Pfizer's willingness or ability to support the captive to change.
The broader captive sector faces growing regulatory scrutiny. The US Internal Revenue Service finalised regulations in 2024 targeting certain micro-captive structures. Separately, the National Association of Insurance Commissioners (NAIC) adopted Actuarial Guideline 55 in 2025 to tighten asset adequacy testing for captive life reinsurance treaties.
Blue Whale operates as a large single-parent corporate captive and falls outside the micro-captive structures targeted by the IRS rules. AM Best rates more than 200 captive and alternative risk transfer vehicles in the United States and internationally.
